Albireo Ltd. has patented new benzothia(di)azepine compounds acting as ileal sodium/bile acid cotransporter (SLC10A2; IBAT; ASBT) and/or sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of diabetes, cardiovascular, gastrointestinal, liver and renal disorders.